Immune Thrombocytopenia Purpura Secondary to COVID-19.

covid-19 immune thrombocytopenia purpura thrombocytopenia

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
09 Jul 2020
Historique:
entrez: 18 7 2020
pubmed: 18 7 2020
medline: 18 7 2020
Statut: epublish

Résumé

A 73-year-old female with past medical history of essential hypertension, hyperlipidemia, seasonal allergies, and chronic back pain presented to the hospital with complaints of headaches, fevers, fatigue, generalized body aches, shortness of breath, and diarrhea. Initial complete blood count was remarkable for leukopenia with an absolute lymph count of 0.60 K/µL and severe thrombocytopenia (platelet count < 3 K/µL). She was tested for COVID-19 via nasopharyngeal swab polymerase chain reaction (PCR) testing and found positive. Additional labs showed an elevated D-dimer, C-reactive protein, fibrinogen, and lactate dehydrogenase. Vitamin B12 and folate levels were obtained and found to be normal. Peripheral smear showed no schistocytes or additional hematologic abnormalities apart from thrombocytopenia. The patient was transfused one unit of platelets with no improvement in platelet count. Fibrinogen count was obtained and found in normal range at 458 mg/dL. Prothrombin time (PT), activated partial thromboplastin time (aPTT), and international normalized ratio (INR) were all found to be normal. Immune thrombocytopenia purpura (ITP) was suspected and intravenous immunoglobulin (IVIG) was administered at a dose of 1 g/kg/day for two doses. By day 4, the patient had marked response to treatment with platelet recovery to 105 K/µL and subsequently discharged by day 5 with complete resolution of symptoms and platelet count of 146 K/µL. Twenty-eight days after discharge, she presented to hematology clinic with platelet count of 8 K/µL. Repeat nasopharyngeal swab PCR COVID testing was negative and she was treated with IVIG and pulse dexamethasone with prompt response, confirming suspicion of underlying, undiagnosed ITP prior to COVID infection.

Identifiants

pubmed: 32676257
doi: 10.7759/cureus.9083
pmc: PMC7362597
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e9083

Informations de copyright

Copyright © 2020, Bennett et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Arch Intern Med. 2009 Feb 23;169(4):357-63
pubmed: 19237719
Blood. 2009 Apr 23;113(17):4086-93
pubmed: 19023115
Br J Haematol. 2009 Jun;146(1):104-12
pubmed: 19438507
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Infect Control Hosp Epidemiol. 2020 Apr 23;:1-2
pubmed: 32321620
Pharmacol Res. 2020 Jun;156:104832
pubmed: 32304747
J Clin Virol. 2020 Jun;127:104362
pubmed: 32305883
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Am Heart Assoc. 2020 Apr 7;9(7):e016219
pubmed: 32233755
Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 14;41(3):245-247
pubmed: 32133824
N Engl J Med. 2020 Apr 30;382(18):e43
pubmed: 32294340
Br J Haematol. 1996 Oct;95(1):145-52
pubmed: 8857953
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013

Auteurs

Joseph Bennett (J)

Internal Medicine, University of Kansas Medical Center, Kansas City, USA.

Christopher Brown (C)

Internal Medicine, University of Kansas Medical Center, Kansas City, USA.

Michael Rouse (M)

Internal Medicine, University of Kansas Medical Center, Kansas City, USA.

Marc Hoffmann (M)

Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, USA.

Zhan Ye (Z)

Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA.

Classifications MeSH